Horizon Health International Corp. Appoints Chairman of the Board

   HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS: HZHI) (Horizon) appoints Dr. Max Arella as Chairman to its Board of Directors.

Mr. Di Fruscia, President of Horizon is delighted to announce that Dr. Max Arella has accepted the appointment as Chairman of the Board of Horizon.

Dr. Arella received his M. Sc. in Microbiology from University of Montreal, Canada and his Ph.D. in Virology from Institute Armand-Frappier-University of Quebec, Canada.

Dr. Arella's career started in France in 1979 as a lecturer during 3 years at the University of Rouen, follow by a post-doctoral fellowship at the prestigious Roche Institute of Molecula Biology in Nutley, New Jersey. In 1984 he accepted a position as a Virology professor at the Institute Armand-Frappier-University of Quebec that was later renamed INRS-Institute Armand-Frappier. Dr. Arella held the position of acting chairman of the Virology Research Center between 1993 and 1998. He collaborated for many years with the private sector in technology-transfert positions and management of intellectual property. He has supervised many master-doctoral and post-doctoral students, published and communicated in molecular biology and virology and collaborated with small, medium and large size pharmaceutical companies developing new pharmaceuticals, medical devices and natural products. Over the years Dr. Arella acquired an impressive network of contacts in the academic, industrial and financial community and he is actively involved in projects in private and public companies. Dr. Arella retired in November 2009.

President Di Fruscia stated: "Dr. Arella brings knowledge, contacts and leadership, invaluable to the future long term growth and inevitable success of Horizon. We are delighted to have Dr. Arella as the Chairman of our organization".

The Company's business:

HORIZON's Subsidiary 'New Release Lactoferrin Pharma Canada Inc.' is an emerging specialty nutraceutical company that is committed to supply its enteric lactoferrin, and new formulations of Lactoferrin and nutraceuticals. We are introducing enteric lactoferrin products in the market as a supplemental food and have also undertaken projects to further study nutraceutical products and increase their market-shares and applications. The company's proprietary enteric lactoferrin, obtained from a licensing agreement from Japan, has proved his efficacy and potential compared to all lactoferrin-containing products.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.

Contacts: Horizon Health International Corp. Rocco Di Fruscia President and CEO 514 586 3799 [e-mail] www.horizonhealthinternational.com